• Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8
• More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib
• Additional analyses from the pivotal LATITUDE PsO 3001 and 3002 studies showed durable skin clearance and rapid and continued improvements in patient-reported itch and quality of life 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.